This drug is indicated as combination therapy with fulvestrant, an estrogen receptor antagonist, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer in patients with a PI3KCA mutation (Markham, 2019a). Here, ERBB2 is linked to breast carcinoma.